Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide - PubMed (original) (raw)
Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide
P D Whitfield et al. J Inherit Metab Dis. 2005.
Abstract
Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme. Enzyme replacement therapy (ERT) offers a specific treatment for patients with Fabry disease, though monitoring of treatment is hampered by a lack of surrogate markers of response. In this study, the efficacy of long-term ERT in six Fabry hemizygotes and two symptomatic heterozygotes has been evaluated. Patients were administered recombinant alpha-galactosidase A every 2 weeks for up to a year. The efficacy of ERT was assessed by monitoring symptomatology and renal function. Urinary glycolipid concentration was estimated by a novel tandem mass spectrometric method. Urine glycolipid (Gb(3)) was elevated at baseline and fell impressively on ERT where patients were hemizygotes and in the absence of renal transplantation. In heterozygotes and in a recipient of a renal allograft, elevations and changes in urine glycolipids were less pronounced. In one patient, after several months of ERT, there was a transient increase in Gb(3) concentrations to baseline (pre-ERT) levels, associated with the presence of antibodies to the recombinant alpha-galactosidase A. The marked decline in urine Gb(3) on ERT, and its subsequent increase in association with an inhibitory antibody response, suggest that this analyte deserves further investigation as a potential marker of disease severity and response to treatment.
Similar articles
- Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, Winchester B. Young E, et al. Acta Paediatr Suppl. 2005 Mar;94(447):51-4; discussion 37-8. doi: 10.1111/j.1651-2227.2005.tb02112.x. Acta Paediatr Suppl. 2005. PMID: 15895713 - Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
Shima H, Tsukimura T, Shiga T, Togawa T, Sakuraba H, Doi T, Ikeda Y, Okamoto T, Yoshikawa Y, Kimura T, Iwase T, Inoue T, Tashiro M, Okada K, Minakuchi J. Shima H, et al. CEN Case Rep. 2024 Aug;13(4):290-296. doi: 10.1007/s13730-023-00843-1. Epub 2023 Dec 22. CEN Case Rep. 2024. PMID: 38135868 Free PMC article. - Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.
Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, Winchester B. Mills K, et al. Eur J Pediatr. 2004 Oct;163(10):595-603. doi: 10.1007/s00431-004-1484-z. Eur J Pediatr. 2004. PMID: 15243806 - Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I, Tuttolomondo A, Di Chiara T, Miceli S, Vogiatzis D, Corpora F, Pinto A. Simonetta I, et al. Curr Gene Ther. 2018;18(2):96-106. doi: 10.2174/1566523218666180404161315. Curr Gene Ther. 2018. PMID: 29618309 Review. - Early therapeutic intervention in females with Fabry disease?
Hughes DA. Hughes DA. Acta Paediatr. 2008 Apr;97(457):41-7. doi: 10.1111/j.1651-2227.2008.00649.x. Acta Paediatr. 2008. PMID: 18339187 Review.
Cited by
- Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M, Lavoie P, Menkovic I, Toupin A, Abaoui M, Elidrissi-Elawad M, Arthus MF, Fortier C, Ménard C, Maranda B, Bichet DG, Auray-Blais C. Boutin M, et al. Int J Mol Sci. 2020 Aug 25;21(17):6114. doi: 10.3390/ijms21176114. Int J Mol Sci. 2020. PMID: 32854306 Free PMC article. - A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A, Mohamed S, Donadio V, Liguori R, Contin M. Perrone A, et al. Molecules. 2021 Dec 3;26(23):7358. doi: 10.3390/molecules26237358. Molecules. 2021. PMID: 34885938 Free PMC article. - Elevated globotriaosylsphingosine is a hallmark of Fabry disease.
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Aerts JM, et al. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2812-7. doi: 10.1073/pnas.0712309105. Epub 2008 Feb 19. Proc Natl Acad Sci U S A. 2008. PMID: 18287059 Free PMC article. - Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up.
Carnicer-Cáceres C, Arranz-Amo JA, Cea-Arestin C, Camprodon-Gomez M, Moreno-Martinez D, Lucas-Del-Pozo S, Moltó-Abad M, Tigri-Santiña A, Agraz-Pamplona I, Rodriguez-Palomares JF, Hernández-Vara J, Armengol-Bellapart M, Del-Toro-Riera M, Pintos-Morell G. Carnicer-Cáceres C, et al. J Clin Med. 2021 Apr 13;10(8):1664. doi: 10.3390/jcm10081664. J Clin Med. 2021. PMID: 33924567 Free PMC article. Review. - Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease.
Ouyang Y, Chen B, Pan X, Wang Z, Ren H, Xu Y, Ni L, Yu X, Yang L, Chen N. Ouyang Y, et al. Exp Ther Med. 2018 Apr;15(4):3733-3742. doi: 10.3892/etm.2018.5889. Epub 2018 Feb 26. Exp Ther Med. 2018. PMID: 29563981 Free PMC article.
References
- Am J Hum Genet. 2001 Mar;68(3):711-22 - PubMed
- FEBS Lett. 2002 Mar 27;515(1-3):171-6 - PubMed
- Eur J Hum Genet. 1996;4(4):219-24 - PubMed
- Clin Chim Acta. 1972 Oct;41:209-17 - PubMed
- Postgrad Med J. 1997 Nov;73(865):710-2 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical